New Jersey A4184 prohibits excessive price increases for essential off-patent and generic prescription drugs and biological products.
New Jersey A4184 aims to prevent excessive price increases for essential off-patent and generic prescription drugs and biological products. The bill defines "price gouging" as an unconscionable increase in the price of a drug or biological product. This includes situations where the price is excessive and not justified by production costs or efforts to expand access. The bill also prohibits price increases that would result in a 30-day supply costing more than $80 at the wholesale acquisition cost. Manufacturers and wholesale distributors are barred from engaging in such price gouging.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.